CN103893133B - A kind of formula of lyophilized excipient preparation and preparation method thereof - Google Patents
A kind of formula of lyophilized excipient preparation and preparation method thereof Download PDFInfo
- Publication number
- CN103893133B CN103893133B CN201210572673.5A CN201210572673A CN103893133B CN 103893133 B CN103893133 B CN 103893133B CN 201210572673 A CN201210572673 A CN 201210572673A CN 103893133 B CN103893133 B CN 103893133B
- Authority
- CN
- China
- Prior art keywords
- preparation
- suspension
- agent
- lyophilized excipient
- binding agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a kind of formula and preparation method of lyophilized excipient preparation, a kind of new simplifying is provided to be formulated, by controlling the proportioning of binding agent and active component in lyophilized excipient preparation, it can make not containing skeleton supporting agent system in lyophilized excipient pharmaceutical formulation material, binding agent and active component are comprised only in formula, the skeleton supporting agent is including but not limited to sugar, sugar alcohol, the amino acid of 2 twelve carbon atoms and inorganic salt and other material.On this basis, other auxiliary materials such as antioxidant, flavouring and essence, skin penetration enhancer, PH conditioning agents can be added.By avoiding using skeleton supporting agent, it can reach and reduce moisture absorption risk, simplify preparation technology, reduce cost, improve the technique effect of unit drugloading rate.
Description
Technical field
It is particularly a kind of by controlling lyophilized excipient the present invention relates to a kind of formula and preparation method of lyophilized excipient preparation
The proportioning of binding agent and active component in preparation, it can make not containing skeleton supporting agent body in lyophilized excipient pharmaceutical formulation material
System, the formula and preparation method of the lyophilized excipient preparation only containing binding agent and active component.
Background technology
Lyophilized excipient technology refers to add skeleton supporting agent in the active component of flowable liquid, semisolid or solid
And itself contain binding agent and skeleton supporting agent in binding agent, or the flowable liquid, semisolid or solid, then will
It is filled into mould, the technology for being able to be molded by freeze drying process, the preparation prepared by freezing excipient technology
Referred to as lyophilized excipient preparation.Because such preparation uses freeze drying process, thermally sensitive composition can be protected not to be destroyed, simultaneously
A large amount of micropores and duct are produced by water sublimed, can have disintegration and dissolution velocity quickly, therefore receive and extensively should
With can apply to the multiple fields such as oral disnitegration tablet, fast-release tablet, chewable tablets, special cosmetics.
Traditional lyophilized excipient matrix includes skeleton supporting agent and binding agent, and skeleton supporting agent is mostly selected from sugar, sugar
Amino acid and inorganic salts (such as sodium phosphate, alumina silicate) of alcohol and 2-12 carbon atom etc. are (referring to Chinese patent
CN200580013010.8)。
When sugar, sugar alcohol, inorganic salts (such as sodium phosphate, alumina silicate) are used as skeleton supporting agent, due to sugar, sugar alcohol and inorganic salts
The hygroscopicity of (such as sodium phosphate, alumina silicate), in process of production be very easy to absorption air in moisture and cause preparation
Skeleton structure composition is collapsed or caved in completely, or make user open packaging when due to rapid moisture absorption sticking to your hands for bringing
Bring the bad influence on use feeling, while also having makes disintegrating procedue many defects such as extend；And amino acid is as skeleton
Though reducing this hygroscopic problem during agent, can not solve this problem, and the Cost Problems of production technology at all
It there is no good solution.
Therefore, exist in this area in lyophilized excipient without using the demand of skeleton supporting agent.But because technology limits
System and traditional concept, and there are no document report lyophilized excipient can be made using only active component and binding agent.Specially
Profit：200580013010 and patent 200410038822 expressly state otherwise in this respect.
The content of the invention
The technical problems to be solved by the invention are to provide a kind of new simplifying and are formulated, and binding agent and work are comprised only in formula
Property composition, it is not added into the skeleton supporting agent in process system, and the skeleton supporting agent is including but not limited to sugared (such as malt
Sugar, trehalose etc.), sugar alcohol (such as mannitol, sorbierite), amino acid (such as glycine, alanine, the glutamic acid of 2-12 carbon atoms
Deng) and the material such as inorganic salts (such as sodium phosphate, alumina silicate).
Inventor dedicates itself to innovation, and has carried out a large amount of in-depth studies and experiment work, finds in the lyophilized excipient preparation of control
The proportioning of binding agent and active component, it can make not containing skeleton supporting agent system in lyophilized excipient pharmaceutical formulation material, and only
The lyophilized excipient preparation that can be conformed to quality requirements is made up of binding agent and active component two parts.On this basis, may be used
To add other auxiliary materials such as antioxidant, flavouring and essence, skin penetration enhancer, PH conditioning agents.By avoiding using bone
Frame supporting agent, it can reach and reduce moisture absorption risk, simplify preparation technology, reduce cost, improve the technique effect of unit drugloading rate.
Hereinafter, the present invention will be described in detail.
Lyophilized excipient preparation provided by the present invention is only made up of binding agent and active component two parts, wherein binding agent with
The weight proportion of active component is binding agent: active component=1: 100 to 100: 1.Experiment display, will beyond this ratio range
The lyophilized excipient preparation to conform to quality requirements can not be prepared.The weight proportion of binding agent and active component can be further
It is preferred that 1: 90 to 90: 1,1: 80 to 80: 1,1: 70 to 70: 1,1: 60 to 60: 1,1: 50 to 50: 1,1: 40 to 40: 1,1: 30 to
30: 1, more preferably 1: 20 to 20: 1,1: 10 to 10: 1,1: 9 to 9: 1,1: 8 to 8: 1,1: 7 to 7: 1, most preferably 1: 6 to 6: 1,1:
5 to 5: 1.Lyophilized excipient preparation provided by the present invention also can further include other auxiliary materials, for example, antioxidant, flavouring and
Essence, skin penetration enhancer, PH conditioning agents etc., the content range of these other auxiliary materials can account for the lyophilized tax being prepared
The 0.1-5% of the total content of type preparation, preferably 0.1-3%..
Active component, which can be dissolved in water, can also be insoluble in the material of water, and described active component can be selected from chemistry
One or more in drug ingedient, traditional Chinese medicine ingredients, natural extract, bioactive ingredients, skin nursing beneficiating ingredient
Combination.
There is no particular limitation for active component involved in the present invention, can be selected from, but not limited to, it is following it is one or more of into
The composition divided.Chemicals (active constituents of medicine)：
Antipyretic-antalgic anti-inflammatory agent, for example, aspirin, Diflunisal, salsalate, paracetamol, Indomethacin,
Brufen, naproxen, Ketoprofen, pirprofen, suprofen, Flurbiprofen, piroxicam, Meloxicam, aulin, benzene bromine horse
It is grand etc.；
Central stimulant, such as pemoline, adrafinil, Piracetam etc.；
Treat migraine agent, such as Sumatriptan succinate；
Antalgesic, such as rotundin, buprenorphine, pentazocine, naloxone etc.；
Anti-parkinson and treatment senile dementia medicine, such as levodopa, compound carbidopa, compound benserazide, hydrochloric acid
Amantadine, piribedil, phenolicamine, donepezil, huperzine are first-class；
Psychotolytic, such as chlorpromazine, fenazil, pethidine, thioridazine, Chlorprothixene, Clozapine, Shu Bi
Profit, Tai Bili, penfluridol, Risperidone etc.；
Antiepileptic and anticonvulsive drug, such as dilantin sodium, carbamazepine, Primidone, Gabapentin, Lamotrigine, third
Natrium valericum, Clonazepam etc..Hypnotic sedative agent, such as diazepam, nitrazepam, Oxazepam, Lorazepam, phenobarbital etc.；
Cholinesterase inhibitor, such as hyoscine etc.；
Antiarrhymic, such as third pyridine, tocainide, mexiletine, aetmozine, dilantin sodium, Propafenone, amine iodine
Ketone etc.；
Antianginal and antiatherosclerotic, such as Propranolol, nifedipine, Gemfibrozil, Bezafibrate, Lip river
Cut down statin, Simvastatin, Pravastatin etc.；
Antihypertensive, such as Enalapril, captopril, Hydrochioro, Amlodipine etc.；
Adrenoceptor blocking agents, such as acebutolol, alprenolol etc.；
Corticosteroid medicine, such as betamethasone, cortisone acetate etc.；
Antidiabetic, such as Repaglinide etc.；
Antithyroid drug, such as propylthiouracil (PTU), Carbimazole, methimazole etc.；
Antithistamine, such as Cetirizine Hydrochloride, Loratadine etc.；
Autacoid, such as dinoprostone, Alprostadil, Betahistine etc.；
Digestive system surgical procedures, such as scopolamine butylbromide, Granisetron Hydrochloride etc.；
Hematological system medicine, such as EPO, cobamamide etc.；
Urinary system medicine, such as azosemide, frusemide etc.；
Reproductive system medicine, such as estrogen, Nandrolone Phenylpropionate etc.；
Antiparasitic agent, such as albendazole, cambendazole etc.；
Antineoplastic, such as aminoglutethimide, amsacrine etc.；
Antimicrobial, such as ampicillin, sulbenicillin sodium etc.；
Tri-Biocin, such as Amoxicillin, cefalexin, Cefprozil, CEFUROXIME AXETIL, ROX, amber second are red
Mycin, josamycin etc..
Traditional Chinese medicine ingredients：
Effective component of chinese medicine monomer, such as：Breviscapinun, qinghaosu, huperzine, tetrahydropalmatine etc.；
Single medicinal material material extract and compound Chinese medicine extract, such as：Tanshinone extract, salvianolic acid extract, answer
Square Danshen Root dropping ball extract, cow-bezoar bolus compound extract, ginseng stem and leave general saponin, asiatic moonseed extract, general ginsenoside,
American ginseng total saponins, Breviscapinun, Glabrous Sarcandra Herb medicinal extract, arasaponin, capillary extract, extractum rhei, andrographolide, mountain
Short, bristly hair or beard leaf extract, asiaticoside, ginkgo biloba p.e etc..Natural plant extracts：As aloe extract, yam extract,
Bilberry fruit P.E, Bitter Melon P.E, Echinacea Purpurea Herb P.E, Feverfew P.E, mangosteen extract, pine needle and pine bark extraction
Thing, Brazilian blackberry extract, mulberries extract, elderberry extract, Cranberry extract, astaxanthin, lycopene, green tea
Extract, grape pip and grape skin extract, glabridin, Paeoniflorin, licoflavone, Cortex Moutan extract etc..Bioactivity into
Point：EGF, bFGF, aFGF, KGF, IGF, NGF, TGF, HGH etc..
Skin nursing beneficiating ingredient：Vitamin A, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin
B12, vitamin C, vitamin D, vitamin E, vitamin K, coenzyme class, protease, metallothionein, pearl and its hydrolysate,
Cow's milk and its extract, pollen and its extract, royal jelly, propolis etc.
The binding agent is edible or a kind of pharmaceutically useful water-soluble high-molecular material, can be polysaccharide, polypeptide, egg
White matter, it is also likely to be synthetic polymeric's macromolecule, or natural macromolecular material or its mixture by remodeling.Conventional is viscous
Knot agent include but is not limited to, glue class (collagen, gelatin, gelatin hydrolysate, Arabic gum, xanthans, carragheen, pectin, konjac glucomannan,
Carrageenan, locust bean gum, natural gum, locust bean gum etc.), cellulose ethers (carboxymethyl cellulose, carboxyethyl cellulose, ethoxy
Methylcellulose, hydroxypropyl methyl cellulose etc.), modified starch series (pulullan, hydroxypropul starch etc., referring to
R.P.Scherer US4305502A), PVP, PVA, hyalomitome acids, albumin, chitosan, dextran, agar, poly- ammonia
Base acid, glycan and its combinations thereof etc.；, it is characterised in that described glue class binding agent is gelatin, gelatin hydrolysate, Arab
Glue, xanthans, carragheen, pectin, konjac glucomannan, carrageenan, locust bean gum, natural gum, locust bean gum；Described cellulose ethers glues
Knot agent is carboxymethyl cellulose, carboxyethyl cellulose, hydroxyethylmethylcellulose, hydroxypropyl methyl cellulose etc.；Described changes
Property starch binding agent be selected from pulullan, hydroxypropul starch, hydroxypropyl methyl starch, pregelatinized starch, amylose, carboxylic first
Base starch, HES, hydroxypropul starch etc.；Described polyaminoacid is selected from polyglutamic acid, polyalanine, polylysine
Deng；Affiliated glycan is selected from fucoidin, synanthrin etc...
The antioxidant includes but is not limited to vitamin C and its derivative, anthocyanidin, resveratrol, plant origin
One or several kinds of mixtures in polyhydric phenols；
The flavouring and essence include but is not limited to mint flavored, chocolate flavoured, fruity, vanilla flavored, caf, tea flavour,
The mixture of the one or more of fragrance of the essence such as corn taste, lemon, milk flavor or more；
The skin penetration enhancer includes but is not limited in lecithin, saponin(e, bay alkyd sodium, azone, tween, sapn
Any or several mixture；
The PH conditioning agents include but is not limited in citric acid, tartaric acid, carbonate, sodium carbonate, phosphate any one
Kind or several mixtures.
Another aspect of the present invention refers to the method for preparing above-mentioned lyophilized excipient preparation, and this method includes：
I. the preparation method of the lyophilized excipient preparation without other auxiliary materials：
(a) solution or suspension injection molding for forming active component, water and binding agent；Or by solid active agent and/or
Binding agent injection molding, add water and be made into suspension；
(b) (a) obtained solution or suspension are de-gassed in quantitative mould；
(c) suspension after the degassing for obtaining (b) or not degassed directly (a) is freezed at low temperature；
(d) preparation that (c) is obtained is freeze-dried in quantitative mould, obtains lyophilized excipient preparation.
II. the preparation method of the lyophilized excipient preparation containing other auxiliary materials：
(a) active component, water, binding agent and other auxiliary materials are formed into suspension injection molding；Or by solid active agent and/or
Binding agent and/or other auxiliary material injection moldings, add water and are made into suspension；
(b) (a) obtained solution or suspension are de-gassed in quantitative mould；
(c) solution after the degassing for obtaining (b) or suspension or not degassed directly (a) is freezed at low temperature；
(d) preparation that (c) is obtained is freeze-dried in quantitative mould, removes solvent, obtain lyophilized excipient preparation.
In both the above method, active component and the weight proportion of binding agent and water are 100: 1 to 1: 100, can enter one
Step ground preferably 1: 90 to 90: 1,1: 80 to 80: 1,1: 70 to 70: 1,1: 60 to 60: 1,1: 50 to 50: 1,1: 40 to 40: 1,1:
30 to 30: 1, more preferably 1: 20 to 20: 1,1: 10 to 10: 1,1: 9 to 9: 1,1: 8 to 8: 1,1: 7 to 7: 1, most preferably 1: 6 to 6:
1,1: 5 to 5: 1.
Wherein Liquid Injection can use the liquid-transfering devices such as accurate quantification pipette, liquid-transfering gun, electronic liquor-transferring rifle, can also adopt
With plunger pump, gear pump, peristaltic pump etc., the solution configured, suspension or suspension are injected into quantitative mould, solid
Injection molding can use accurate solid measurer, vibrations capillary flow of powder controller,；
The method that wherein deaerates can use centrifugal degassing method, vacuum outgas method and ultrasonic degassing method etc.；
Wherein freezing can use liquid nitrogen or liquid, drikold spray refrigeration or sleeve pipe cooling back installation
Mode, turbine expander refrigeration mode or cascade refrigeration mode, at -20 DEG C -- at a temperature of 196 DEG C, rapidly by solution, suspension
Or suspension freezing turns into solid；
Wherein the lyophilized vacuum using 0.01-20 millibars, temperature freeze between -70 DEG C to 50 DEG C scopes；
Embodiment
The present invention is further illustrated by the following examples, but the present invention is not restricted to this.
In following examples and comparative example, the evaluation method for freezing excipient preparation is as follows：
1) disintegration time：
By in test tube of the preparation input equipped with 2 milliliters of 37 degree water Celsius, the disintegration completely of observation preparation and 20 mesh sieves when
Between；
2) friability：
By preparation from one meter of high position in a manner of freely falling body, drop in stainless steel platform, cast 100, measure
Always come off powder, and 3% of weight less than total formulation weight is qualified.
3) formulation aesthetics：
The lyophilized excipient preparation finger of preparation is firmly taken out into preparation from aluminium nest is bottom up, visually observes outward appearance shape
Looks, smoothness, whether it is recessed, crackle etc.；
Embodiment 1：
Vitamin C: collagen=100: 1, vitamin C 100mg, it is accurate filling into 0.3m1 moulds, collagen 1mg, add
After being dissolved in 0.2ml water, be poured into containing in the ascorbic moulds of 100mg, stirring makes moisture be dispersed in powder, it is quick-frozen to-
It is 100 degrees Celsius, lyophilized to turn into solid beverage.
Embodiment 2：
Pearl powder: hyaluronic acid=1: 100, hyaluronic acid 100mg, wherein 90mg hyaluronic acids mix with 1mg pearl fine powders
Accurately filling to enter in 0.5ml moulds after conjunction, 10mg hyaluronic acids are poured into containing 90mg hyalomitomes after the dissolving of 0.3ml water
In the mould of acid and 1mg pearl powders, stirring makes moisture be dispersed in powder, quick-frozen to -196 degrees Celsius, lyophilized to turn into skin care solid
Elite.
Embodiment 3：
Bilberry fruit P.E: Propiram=5: 1, Bilberry fruit P.E 60mg and Propiram 12mg add water 0.4ml to be configured to solution,
Filling to enter 0.4 milliliter of mould, freezing turns into solid beverage.
Embodiment 4：
Arasaponin: PVP=10: 1, arasaponin 500mg, PVP50mg, wherein PVP40mg add water 0.5ml to prepare
Into solution, arasaponin 100mg and PVP10mg irrigate into 0.5 milliliter of mould in powder form, afterwards with
The solution that PVP40mg adds water 0.5ml to be configured to disperses, and being freezed in mould turns into buccal tablet.
Embodiment 5：
Total Ginkgo Flavone-Glycoides: PVA=1: 1, Total Ginkgo Flavone-Glycoides 20mg, PVA20mg, add water 0.3ml to be configured to solution, be poured into
Enter 0.3 milliliter of mould, being freezed in mould turns into buccal tablet.
Embodiment 6：
Resveratrol: polylysine=5: 1, resveratrol 100mg, polylysine 20mg, suspension is configured to, is poured into
Enter 0.4 milliliter of mould, being freezed in mould turns into buccal tablet.
Embodiment 7：
Loratadine: dextran=1: 10, Loratadine 10mg, Dextran 100 mg wherein Loratadine 10mg with
Dextran 5 0mg is dispersed into 0.2ml moulds, 50mg dextrans are configured to solution with 0.2ml water, are poured into as powder
Enter 0.2ml moulds, mixed with powder, being freezed after stirring in mould turns into buccal tablet.
Embodiment 8：
Paracetamol: PVA=25: 1, paracetamol 500mg and PVA20mg, perfusion enter 1ml shaping moulds
Tool, mixture are divided into two parts, and paracetamol 500mg powder fillings enter 0.6 milliliter of mould, PVA20mg with
0.4ml water dissolves, and perfusion enters in 500mg powder, is freezed after stirring, turns into paracetamol medicine.
Embodiment 9：
Cranberry extract: hydroxypropyl methyl cellulose=25: 1, Cranberry extract 500mg perfusion enter 0.8ml moulds
Have, hydroxypropyl methyl cellulose 20mg, add water 1ml to dissolve, perfusion enters in 500mg powder, is freezed after stirring, turns into and is got over to climing
Certain kind of berries solid beverage.
Embodiment 10：
Selegiline: polyglutamic acid=1: 10, selegiline 1mg, polyglutamic acid 10mg, irrigated after being dissipated with 0.1ml moisture
Into 0.1ml moulds, freezed after freezing, turn into selegiline medicine.
Embodiment 11：
Vitamin B6: hydroxypropul starch=2: 1, vitamin B6 10mg, hydroxypropul starch 5mg, filled after being dissipated with 0.1ml moisture
Note enters 0.1ml moulds, is freezed after freezing, turns into vitamin B6 medicine.
Embodiment 12：
Aspirin: xanthans+Propiram=10: 1, aspirin 500mg, xanthans 10mg, Propiram 40mg, wherein
Aspirin 500mg perfusions enter 0.5ml moulds, after xanthans 10mg, Propiram 40mg are disperseed with the dissolving of 0.5ml water, perfusion
Into in 500mg aspirin powder, freeze, turn into aspirin medicine after stirring.
Table 1：Test result
| Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 | Embodiment 5 | Embodiment 6 | |
| Disintegration time | 5S | 5S | 3S | 15S | 15S | 15S |
| Outward appearance | It is smooth | It is smooth | It is smooth | It is smooth | It is smooth | It is smooth |
| Friability | ＜ 3% | ＜ 3% | ＜ 3% | ＜ 3% | ＜ 3% | ＜ 3% |
| Embodiment 7 | Embodiment 8 | Embodiment 9 | Embodiment 10 | Embodiment 11 | Embodiment 12 | |
| Disintegration time | 5S | 15S | 15S | 5S | 3S | 15S |
| Outward appearance | It is smooth | It is smooth | It is smooth | It is smooth | It is smooth | It is smooth |
| Friability | ＜ 3% | ＜ 3% | ＜ 3% | ＜ 3% | ＜ 3% | ＜ 3% |
It should be noted that can arbitrarily be changed for the various details of the present invention, but certainly, these are repaiied
Change and fall within protection scope of the present invention.
Claims (5)
1. a kind of lyophilized excipient preparation, is only made up of active component and binding agent and is free of skeleton supporting agent, it is characterised in that living
Property composition be selected from resveratrol and binding agent and be selected from polylysine, the weight proportion of wherein binding agent and active component is：Bond
Agent：Active component=1:100 to 100:1.
2. lyophilized excipient preparation as claimed in claim 1, it is characterised in that wherein also contain other auxiliary materials, other auxiliary materials
For the one or more in antioxidant, flavouring, skin penetration enhancer, pH adjusting agent.
3. lyophilized excipient preparation as claimed in claim 2, it is characterised in that described antioxidant is selected from vitamin C, plant
One or several kinds of mixtures in the polyhydric phenols in source；The flavouring is selected from mint flavored, chocolate flavoured, vanilla
One or more of mixtures in taste, caf, tea flavour, corn taste, lemon, milk flavor；Described Transdermal absorption
Accelerator is selected from any of lecithin, tween, sapn or several mixtures；Described pH adjusting agent be selected from citric acid,
Any one of tartaric acid, sodium acid carbonate, sodium carbonate or several mixtures.
4. the preparation method of lyophilized excipient preparation as claimed in claim 1, it is characterised in that this method is：
(a) solution or suspension injection molding for forming active component, water and binding agent；Or by solid active agent and/or glue
Agent injection molding is tied, water is added and is made into suspension or suspension；
(b) solution, suspension or the suspension obtained (a) is de-gassed in quantitative mould；
(c) solution, suspension or the suspension after (a) degassing that directly either (b) is obtained are freezed at low temperature；
(d) preparation that (c) is obtained is freeze-dried in quantitative mould, obtains lyophilized excipient preparation.
5. the preparation method of lyophilized excipient preparation as claimed in claim 2, it is characterised in that this method is：
(a) active component, water, binding agent and other auxiliary materials are formed into solution or suspension injection molding；Or by solid active agent
And/or binding agent and/or other auxiliary material injection moldings, add water and be made into suspension or suspension；
(b) solution, suspension or the suspension obtained (a) is de-gassed in quantitative mould；
(c) solution, suspension or the suspension of (a) directly or after (b) obtained degassing are freezed at low temperature；
(d) preparation that (c) is obtained is freeze-dried in quantitative mould, removes solvent, obtain lyophilized excipient preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210572673.5A CN103893133B (en) | 2012-12-26 | 2012-12-26 | A kind of formula of lyophilized excipient preparation and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210572673.5A CN103893133B (en) | 2012-12-26 | 2012-12-26 | A kind of formula of lyophilized excipient preparation and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103893133A CN103893133A (en) | 2014-07-02 |
| CN103893133B true CN103893133B (en) | 2018-03-09 |
Family
ID=50984929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210572673.5A Active CN103893133B (en) | 2012-12-26 | 2012-12-26 | A kind of formula of lyophilized excipient preparation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103893133B (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105883218A (en) * | 2014-10-29 | 2016-08-24 | 李和伟 | Solid-liquid separation prepared-immediate-used packing device and preparation method thereof |
| CN107233217A (en) * | 2016-03-25 | 2017-10-10 | 李和伟 | A kind of lyophilized formulations containing surfactant and its wash shield product |
| CN107224407A (en) * | 2016-03-25 | 2017-10-03 | 李和伟 | A kind of lyophilized formulations containing biology enzyme and its shield tooth product mix |
| CN107260557A (en) * | 2016-04-07 | 2017-10-20 | 董玲 | A kind of rolling modulus method prepares method of lyophilized formulations and products thereof |
| CN107468528A (en) * | 2016-06-07 | 2017-12-15 | 董玲 | A kind of lyophilized formulations and preparation method thereof |
| CN107714654A (en) * | 2016-08-11 | 2018-02-23 | 董玲 | A kind of lyophilized formulations and preparation method thereof |
| CN108567745A (en) * | 2017-03-10 | 2018-09-25 | 常州柚盾实业投资有限公司 | A kind of lyophilized excipient and preparation method thereof containing active constituent |
| CN108619522A (en) * | 2017-03-15 | 2018-10-09 | 常州柚盾实业投资有限公司 | A kind of lyophilized excipient and preparation method thereof containing phenolic acid |
| CN110724597A (en) * | 2018-07-17 | 2020-01-24 | 山东坦途农业科技有限公司 | Active oil freeze-dried preparation and preparation method and application thereof |
| CN109157657A (en) * | 2018-09-29 | 2019-01-08 | 商丘美兰生物工程有限公司 | Infectious bursal disease live-vaccine heat-proof freeze drying protectant and preparation method thereof |
| CN112655769A (en) * | 2020-12-21 | 2021-04-16 | 山东天源人乳库科技发展有限公司 | Human milk flash-release tablet and preparation method thereof |
| CN112842931B (en) * | 2021-02-04 | 2023-05-09 | 胶原蛋白(武汉)生物科技有限公司 | Animal collagen freeze-dried ball, cosmetic set and preparation process |
| CN112971150B (en) * | 2021-04-06 | 2022-10-14 | 河北菲瑞生物技术有限公司 | Gamma-aminobutyric acid sugar-containing freeze-dried flash-release tablet and preparation method thereof |
| CN113801926B (en) * | 2021-09-23 | 2024-07-23 | 湖北海卓生物科技有限公司 | Freeze-drying protective agent of molecular detection reagent and application thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1220486C (en) * | 2002-11-15 | 2005-09-28 | 董英杰 | resveratrol , piceid and its derivative and its preparation |
| US20060024370A1 (en) * | 2004-07-29 | 2006-02-02 | Cephalon France | Modafinil oral lyophilizate |
| CN101757030A (en) * | 2010-03-19 | 2010-06-30 | 董玲 | Cartialgenous all-component uniform freeze-dried preparation and production method thereof |
| CN102258454A (en) * | 2010-05-26 | 2011-11-30 | 董玲 | Coated freeze-drying excipient |
| CN101927148A (en) * | 2010-07-28 | 2010-12-29 | 河北农业大学 | Method for improving stability and water solubility of resveratrol and application |
| CN102462665B (en) * | 2010-11-18 | 2016-12-07 | 董玲 | The preparation method of lyophilized excipient |
-
2012
- 2012-12-26 CN CN201210572673.5A patent/CN103893133B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103893133A (en) | 2014-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103893133B (en) | A kind of formula of lyophilized excipient preparation and preparation method thereof | |
| CN103893770B (en) | A kind of freeze-drying excipient preparation and preparation method thereof | |
| CN104644571B (en) | Freeze-drying excipient protection device and preparation method thereof | |
| CN104644568A (en) | Protective apparatus and preparation method of freeze-dried excipient preparation containing active components and binding agent | |
| CN106551804B (en) | A method for preparing freeze-dried excipients using roll moulding and products thereof | |
| CN103318551A (en) | System for packaging and delivering freeze-dried excipient and preparation method of freeze-dried excipient | |
| WO2018028531A1 (en) | Lyophilized preparation and preparation method therefor | |
| CN104417918A (en) | Freeze-drying excipient packing and transferring system and production method thereof | |
| CN101919805B (en) | Freeze-dried molded products containing magnesium ascorbyl phosphate | |
| CN106963737A (en) | A kind of any form of easy disintegrating freezes shaped preparation and preparation method thereof | |
| CN107468528A (en) | A kind of lyophilized formulations and preparation method thereof | |
| CN107714654A (en) | A kind of lyophilized formulations and preparation method thereof | |
| CN100584385C (en) | Tablet and its preparation method | |
| CN106466228A (en) | A kind of multi-mould prepares method of lyophilized excipient of arbitrary shape and products thereof | |
| CN106852907A (en) | A kind of production method of soluble lyophilized film and products thereof | |
| CN106821770A (en) | It is a kind of to prepare method of lyophilized formulations of arbitrary shape and products thereof | |
| US20180200150A1 (en) | Freeze-drying excipient preparation of arbitrary shape and preparation method therefor | |
| CN108066152A (en) | A kind of preparation method of lyophilized excipient | |
| CN107280979A (en) | It is a kind of to prepare method of lyophilized formulations of arbitrary shape and products thereof | |
| CN107260557A (en) | A kind of rolling modulus method prepares method of lyophilized formulations and products thereof | |
| CN205274216U (en) | Solid -liquid separation joins in marriage packing plant of usefulness promptly | |
| CN107296796A (en) | A kind of formula of lyophilized formulations and preparation method thereof | |
| CN106619539A (en) | Method for preparing freeze-dried excipient preparation in any shape and product of method | |
| CN106560096A (en) | Delivery and dissolving device of lyophilized excipient preparation | |
| CN107281113A (en) | A kind of formula of lyophilized formulations and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DD01 | Delivery of document by public notice |
Addressee: Li Hewei Document name: Notification of Passing Examination on Formalities |
|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20191213 Address after: 101300 Beijing city Shunyi District zhaoquanying Zhaofeng industrial base Park Ying Road No. 7 Patentee after: BEIJING MEFOOD HEALTH TECHNOLOGY Co.,Ltd. Address before: 101312, 6, Anqing Avenue, B District, Shunyi District Airport Industrial Zone, Beijing, 1 Patentee before: Li Hewei |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20201210 Address after: Huihe Industrial Park, Zhaili Town, Laiwu nonggao District, Jinan City, Shandong Province Patentee after: Shandong Tantuo Agricultural Technology Co.,Ltd. Address before: 101300 Zhaofeng Town, Shunyi District, Beijing Zhaofeng industrial base 7 Yuan Ying Road Patentee before: BEIJING MEFOOD HEALTH TECHNOLOGY Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220829 Address after: Tianning District Hehai road 213000 Jiangsu city of Changzhou province No. 9 Patentee after: CHANGZHOU YOUDUN INDUSTRIAL INVESTMENT CO.,LTD. Address before: Huihe Industrial Park, Zhaili Town, Laiwu nonggao District, Jinan City, Shandong Province Patentee before: Shandong Tantuo Agricultural Technology Co.,Ltd. |
|
| TR01 | Transfer of patent right |